Limitations, agreements, and source contact

Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial · Source last updated 2025-05-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restriction Type

LTE60

restrictive Agreement

true

limitations And Caveats

description

Only one patient was enrolled on this study. Due to the concern on confidentiality, individual data is not reported.

point Of Contact

email

eatrials@jimmy.harvard.edu

organization

ECOG-ACRIN Statistical Office

phone

617-632-3012

title

Study Statistician

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice